Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
24.82
+0.82 (3.42%)
At close: Mar 9, 2026, 4:00 PM EDT
24.82
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:02 PM EDT
Company Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor.
The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jan 31, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 354 |
| CEO | Todd Watanabe |
Contact Details
Address: 3027 Townsgate Road, Suite 300 Westlake Village, California 91361 United States | |
| Phone | 805 418 5006 |
| Website | arcutis.com |
Stock Details
| Ticker Symbol | ARQT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001787306 |
| CUSIP Number | 03969K108 |
| ISIN Number | US03969K1088 |
| Employer ID | 81-2974255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Todd Franklin Watanabe M.A. | President, Chief Executive Officer and Director |
| Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder and Director Emeritus |
| Masaru Matsuda Esq., J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Patrick E. Burnett M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Larry Todd Edwards | Executive Vice President and Chief Commercial Officer |
| Latha Vairavan | Chief Financial Officer |
| Rajvir Madan | Chief Digital and Technology Officer |
| Brian Schoelkopf | Head of Investor Relations |
| Steve Arias | Vice President of Compliance and Privacy |
| Amanda Sheldon | Head of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 25, 2026 | 10-K | Annual Report |